• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

AXIM Biotech Holds Annual Board Meeting

January 25, 2017

 

NEW YORK, Jan. 25, 2017 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (AXIM®Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, held its second annual board meeting on January 20, 2017 in New York City. AXIM Biotech board members reviewed company milestones in 2016, and discussed clinical trial progress for irritable bowel syndrome (IBS), multiple sclerosis (MS) and psoriasis and eczema (PSO) as well as additional R&D activities for the next 12 months. The meeting also approved budgets needed to carry out the clinical projects and business developments.

 

Management and advisory board experts considered further proof of concept studies of cannabis based treatment for indications such as nicotine addiction, Restless Leg Syndrome, postherpetic neuralgia, and drug related psychosis. Other items discussed during the board meeting included progress on vertical integration with the manufacturing facility in Almere, Netherland, use of natural versus synthetic cannabinoids and antibacterial preparations with CBG, CBD and halogenated metals.

 

“AXIM achieved exciting milestone developments in 2016,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech. “We are entering the New Year with a robust clinical pipeline in IBS, MS and PSO and expanded study for additional therapeutic indications. We are fortunate to have research collaboration with leading experts, and will continue to optimize our company structure to execute our business goals. With our patented delivery technology and broad research and product portfolio, AXIM is becoming a leader in the cannabis-based pharmaceutical space.”

 

About AXIM®


AXIM® Biotechnologies, Inc. (OTC:AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. Medical Marijuana, Inc. is a major investor in AXIM. For more information, please visit www.AXIMBiotech.com.

 

About CanChew® and CanChew Plus®


CanChew® is a unique hemp-derived CBD functional chewing gum that is distinctly different than any other brands of gum on the market. Features listed on the CanChew® website include:

  • Non-habit forming

  • No prescription needed

  • Available in all 50 states

  • Great-tasting mint gum has no artificial sweeteners or preservatives

  • Non-GMO, gluten free, vegan and kosher

CanChew Plus® is a vastly improved delivery system than the alpha version of CanChew® Gum. It is produced by a leading European functional gum manufacturer.

 

Featured in Healthy Living Magazine, CanChew® was also recognized by the HealthyLivinG Foundation and honored with its Triple Leaf Award.

FORWARD-LOOKING DISCLAIMER


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.

LEGAL DISCLOSURE


AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

 

For the original press release, click here

Read more articles tagged:

Please reload

LATEST NEWS
Please reload

Please reload

DMO

© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.